These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32711786)

  • 1. Ukrainian health authorities adopt hepatitis C project.
    Devi S
    Lancet; 2020 Jul; 396(10246):228. PubMed ID: 32711786
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Cohen J
    Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
    [No Abstract]   [Full Text] [Related]  

  • 4. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MSF pushes down price of generic hepatitis C drugs to new low level.
    Wise J
    BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
    [No Abstract]   [Full Text] [Related]  

  • 6. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the role of sofosbuvir in treating hepatitis C infection?
    Carey L
    JAAPA; 2015 Feb; 28(2):16-9. PubMed ID: 25621961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in hepatitis C therapies.
    Mariño Z; Lens S; Gambato M; Forns X
    Expert Opin Pharmacother; 2015; 16(13):1929-43. PubMed ID: 26219918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
    Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
    Elmowafy AY; El Maghrabi HM; Zahab MA; Elwasif SM; Bakr MA
    Iran J Kidney Dis; 2018 Nov; 12(6):382-384. PubMed ID: 30595569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Zhao Q; Xia N
    Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients.
    D'Ambrosio R; Vinci M; Franchina M; Parlati L; Zaltron S; Pasulo L; Campise M; Messa P; Pol S; Lampertico P
    Kidney Int; 2019 Apr; 95(4):993-995. PubMed ID: 30904073
    [No Abstract]   [Full Text] [Related]  

  • 15. Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
    Uribe-Noguez LA; Ocaña-Mondragón A; Mata-Marín JA; Cázares-Cortázar A; Ribas-Aparicio RM; Gómez-Torres ME; Gaytán-Martínez J; Martínez-Rodríguez ML
    J Infect Chemother; 2018 Nov; 24(11):928-931. PubMed ID: 29773440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
    Schmitz J
    Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
    [No Abstract]   [Full Text] [Related]  

  • 17. Indian hepatitis C drug patent decision shakes public health community.
    't Hoen EFM
    Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
    Gao XH; Jing P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):457-459. PubMed ID: 31357763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
    Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.